Despite higher rates of neutropenia, the infrequent discontinuation of doses in trials combining venetoclax with monoclonal antibody therapy can be attributed to the administration of G-CSF to nearly half of the patients in these studies. This evidence concerns the gene CSF3 and neutropenia.